Remplir Regulatory Application for US$750m EU-UK Market

• Orthocell has submitted its application to the British Standards Institution (BSI) seeking approval to commercially distribute Remplir™ into the US$750 million1 EU and UK nerve repair market, comprising an estimated 500,000 surgical repairs of peripheral nerves per year. • Regulatory approval expected to be received in 3Q CY26. • Orthocell requires certifications, known as “CE” and “UKCA”, from